natgillin/translations-raw huggingface dataset:
burning sensation, partial loss of sensitivity, feeling of “pins and needles” or numbness
pekoč občutek, delna izguba občutkov, mravljinčenje ali odrevenelost;
Burning sensation1
pekoč občutek1
Burning sensation;
pekoč občutek,
burning when passing water diarrhoea.
pekoč občutek pri uriniranju drisko
Burning, itching, redness and warmth at infusion site, redness at injection site
pekoč občutek, srbenje, rdečina in občutek toplote na mestu infuzije, rdečina na vbodnem mestu,
burning, pricking/tingling sensation or diminished sensitivity to sensation
pekoč, pikajoč/mravljinčast občutek ali zmanjšan občutek za otip
burning, prickling, itching or tingling skin sensation
pekoč, zbadajoč, srbeč ali mravljinčast občutek v koži,
burning, prickling, numbness or tingling sensation of skin
žarenje, ščemenje, otrplost ali zbadanje kože
Burns
opekline
Burns for which there is limited or no experience
Opekline, pri katerih je izkušenj malo oz. izkušenj ni
Burns second degree, accidental exposure (including eye pain, eye and throat irritation and cough)
opekline druge stopnje, nenamerna izpostavljenost zdravilu (vključno bolečina v očesu, draženje oči in žrela ter kašelj)
Burping
pahovanje
Burping
pahovanje;
burping
riganje
burping
riganje,
burping, indigestion, gastroenteritis
riganje, slaba prebava, gastroenteritis
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind
pahovanje, siljenje na bruhanje, bruhanje, zgaga, bolečine v trebuhu, suha usta, vetrovi
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
pahovanje, siljenje na bruhanje, bruhanje, zgaga, bolečine v trebuhu, suha usta, vetrovi,
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
pahovanje, siljenje na bruhanje, bruhanje, zgaga, bolečine v želodcu, suha usta, vetrovi,
burping, stomach ache, changes in your stools such as being oily, urgent need for bowel movements, painful bowel movements
pahovanje, bolečine v trebuhu, spremembe pri blatu, npr. oljnato blato, nujna potreba po odvajanju blata, boleče odvajanje blata
Busilvex 6 mg/ml concentrate for solution for infusion busulfan
Busilvex 6 mg/ml koncentrat za raztopino za infundiranje busulfan
Busilvex 6 mg/ml concentrate for solution for infusion. busulfan.
Busilvex 6 mg/ml koncentrat za raztopino za infundiranje busulfan
Busilvex 6 mg/ml sterile concentrate IV
Busilvex 6 mg/ml sterilen koncentrat i.v.
Busilvex as well as busulfan has not been studied in patients with hepatic impairment.
Raziskav zdravila Busilvex in busulfana pri bolnikih z okvaro jeter niso izvajali.
Busilvex is given as a central intravenous infusion (drip into a central vein in the chest).
Zdravilo Busilvex se daje kot intravenska infuzija skozi osrednji venski kateter (kapalna infuzija v osrednjo veno v prsnem košu).
Busilvex is used in adults and children as part of a ‘conditioning’ (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells).
Zdravilo Busilvex se uporablja pri odraslih in otrocih kot del pripravljalnega zdravljenja pred presaditvijo krvotvornih matičnih celic (celic, ki tvorijo krvne celice).
Busilvex must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Zdravilo Busilvex morate pred uporabo razredčiti z 0,9 % raztopino natrijevega klorida (9 mg/ml) ali 5 % raztopino glukoze za injiciranje.
Busilvex must be prepared by a healthcare professional using sterile transfer techniques.
Zdravilo Busilvex mora pripraviti usposobljen zdravstveni delavec ali delavka v sterilnih pogojih.
Busilvex must not be put into an intravenous bag that does not contain sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Zdravila Busilvex ne smete dati v intravensko vrečko, v kateri ni 0,9 % raztopine natrijevega klorida (9 mg/ml) za injiciranje ali 5 % raztopine glukoze za injiciranje.
Busilvex will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
Zdravilo Busilvex se daje v odmerku 3,2 mg/kg kot 3-urna infuzija enkrat na dan nemudoma po fludarabinu, 2 ali 3 dni zaporedoma.
Busilvex will be administered every 6 hours during 4 consecutive days prior to transplant.
Zdravilo Busilvex boste 4 zaporedne dneve pred presaditvijo prejemali vsakih 6 ur.
Buspirone
Za zdravljenje pljučne
buspirone - used to make you calmer
buspiron - za pomiritev
Buspirone Clorazepate Diazepam Estazolam Flurazepam
buspiron klorazepat diazepam estazolam flurazepam
Buspirone Clorazepate Diazepam Estazolam Flurazepam Zolpidem
buspirone klorazepat diazepam estazolam flurazepam zolpidem
Buspirone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A and as a result is expected to increase the plasma concentrations of buspirone.
Ritonavir, odmerjan kot farmakokinetični stopnjevalec ali kot protiretrovirusno zdravilo, zavira CYP3A, zato je treba pričakovati, da zviša koncentracijo buspirona v plazmi.
Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam that is not taken orally, zoldipem (sedative agents)
buspiron, klorazepat, diazepam, estazolam, flurazepam, midazolam, kadar se uporablja v obliki za injiciranje, zoldipem (pomirjevala)
buspirone, clorazepate, diazepam, estazolam, flurazepam, perphenazine, risperidone, thioridazine, zolpidem, medicines used to treat nervous system disorders
buspirone, klorazepat, diazepam, estazolam, flurazepam, perfenazin, risperidon, tioridazin, zolpidem; zdravila za zdravljenje bolezni živčevja
Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem
buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem
buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem and lorazepam
buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem in lorazepam
buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, medicines used to treat nervous system disorders
buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem, zdravila, ki se uporabljajo za zdravljenje motenj živčnega sistema
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion
Busulfan Fresenius Kabi 6 mg/ml koncentrat za raztopino za infundiranje
Busulfan Fresenius Kabi in combination with cyclophosphamide:
Zdravilo Busulfan Fresenius Kabi v kombinaciji s ciklofosfamidom
Busulfan Fresenius Kabi in combination with fludarabine
Zdravilo Busulfan Fresenius Kabi v kombinaciji s fludarabinom
Busulfan Fresenius Kabi is a ‘generic medicine’.
Zdravilo Busulfan Fresenius Kabi je „generično zdravilo“.
Busulfan Fresenius Kabi must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Zdravilo Busulfan Fresenius Kabi je potrebno pred uporabo razredčiti z 0,9 % raztopino natrijevega klorida za injiciranje (9 mg/ml) ali s 5 % raztopino glukoze za injiciranje.
Busulfan Fresenius Kabi must not be put into an intravenous bag that does not contain sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Zdravila Busulfan Fresenius Kabi ne smete dati v vrečko, v kateri ni 0,9 % raztopine natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopine glukoze za injiciranje.
Busulfan Fresenius Kabi will be administered every 6 hours during 4 consecutive days prior to transplant.
Zdravilo Busulfan Fresenius Kabi boste prejemali vsakih 6 ur, 4 dni zaporedoma pred presaditvijo.
Busulfan has not been studied in patients with hepatic impairment.
Pri bolnikih z okvaro jeter raziskave busulfana niso bile izvedene.
Busulfan in combination with cyclophosphamide In adults
Busulfan v kombinaciji s ciklofosfamidom Odrasli
Busulfan in combination with cyclophosphamide or melphalan
Busulfan v kombinaciji s ciklofosfamidom ali melfalanom
Busulfan in combination with fludarabine (FB) In adults
Busulfan v kombinaciji s fludarabinom (FB) Odrasli
Busulfan is metabolised mainly through conjugation with glutathione (spontaneous and glutathione-S- transferase mediated).
Busulfan se presnavlja predvsem s konjugacijo z glutationom (ki je lahko spontana ali pa pri njej sodeluje glutation-S-transferaza).
Busulfan is used before transplantation to destroy abnormal cells and the patient’s existing blood- making cells.
Zdravilo Busulfan Fresenius Kabi se uporablja pred presaditvijo, da se uničijo nenormalne celice in obstoječe bolnikove krvotvorne celice.
Busulfan is used before transplantation to destroy abnormal cells and the patient’s existing haematopoietic progenitor cells.
Zdravilo Busulfan se uporablja pred presaditvijo, da se uničijo nenormalne celice in obstoječe bolnikove krvotvorne matične celice.
Busulfan will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
Busulfan je treba uporabiti v enkratnem dnevnem odmerku 3,2 mg/kg v 3-urni infuziji, takoj po fludarabinu, 2 ali 3 dni zapored.
Busulfan will be administered every 6 hours during 4 consecutive days prior to transplant.
Zdravilo Busulfan Fresenius Kabi boste prejemali na vsakih 6 ur, 4 dni zaporedoma pred presaditvijo.
Busulfan will be administered once daily during 2 or 3 consecutive days prior to transplant.
Zdravilo Busulfan Fresenius Kabi boste prejemali enkrat dnevno, 2 ali 3 dni zaporedoma pred presaditvijo.
But be sure to choose a different injection site in that area.
Pazite, da v tem delu izberete različno mesto injiciranja.
But be sure to choose a different injection site within that area.
Vendar pa morate na tem delu telesa izbirati različna mesta injiciranja.
But if Tamiflu is stopped earlier than your doctor told you, the symptoms of flu may come back.
Vendar, če pa prenehate z jemanjem zdravila Tamiflu prej, kot vam je predpisal zdravnik, se lahko simptomi gripe ponovijo.
But not breathing out into the inhaler.
Ne izdihavajte v inhalator.
But these reactions subside within a short time (maximum of two days) without treatment.
Vendar te reakcije čez kratek čas (največ dva dni) izzvenijo brez zdravljenja.
But you must be aware that they are potentially serious — so, if you notice any of these symptoms:
Vendar se morate zavedati, da so lahko resni, zato v primeru, da opazite katerega od njih:
But you must be aware that they are potentially serious — so, if you notice any of these symptoms:
Vendar se morate zavedati, da so lahko resni, zato v primeru, da opazite katerega od teh simptomov:
But your doctor will have told you exactly how much to use, when to use it, and how often.
Vaš zdravnik vam bo povedal, natančno koliko zdravila potrebujete, kdaj ga uporabite in kako pogosto.
Button
gumb
button is all the
injiciranje
button on top.
gumb na vrhu.
Butyl elastomer closure and aluminium cap.
Zamašek iz butilnega elastomera in aluminijska zaporka za vialo.
Butylated hydroxyanisole Macrogol 400
Butiliran hidroksianizol Makrogol 400
Butylated hydroxytoluene Dipropylene glycol methyl ether Isopropyl alcohol
Butilhidroksitoluen Dipropilen glikol metil eter Izopropilalkohol
Butylhydroxyanisole (E320)
Ovojnica kapsule
Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Ethanol, anhydrous Polysorbate 80 (E433) Povidone
Butilhidroksianizol (E320) Butilhidroksitoluen (E321) Etanol, brezvodni Polisorbat 80 (E433) Povidon
Butylhydroxyanisole (E320) Lactose monohydrate Sodium laurilsulfate
butilhidroksianizol (E320), laktoza monohidrat, natrijev lavrilsulfat,
Butylhydroxytoluene (E321) 1 mg/ml.
Butilhidroksitoluen (E321) 1 mg/ml
Butylhydroxytoluene (E321) Diethylene glycol monoethyl ether
Butilhidroksitoluen (E321) Dietilen glikol monoetileter
Butylhydroxytoluene (E321) Sorbic acid (E200)
Butilhidroksitoluen (E321) Sorbinska kislina (E200) Sončnično olje
Butylhydroxytoluene (E321): 1 mg For the full list of excipients, see section 6.1.
Butilhidroksitoluen (E321) 1 mg Za celoten seznam pomožnih snovi glejte poglavje 6.1.
butylhydroxytoluene (E321; as antioxidant) 0.9 mg sorbic acid (E200; as preservative) 0.7 mg
butilhidroksitoluen (E321; kot antioksidant) 0,9 mg sorbinska kislina (E200; kot kozervans) 0,7 mg
Butylhydroxytoluene 1 mg/ml (E 321; as antioxidant).
1 mg/ml butilhidroksitoluena (E 321; kot antioksidant).
Butylhydroxytoluene 1 mg/ml (E 321; as antioxidant).
1 mg/ml butilhidroksitoluena (E321; kot antioksidant).
buzzing, hissing, whistling, ringing or other persistent noise in the ears
brenčanje, piskanje, žvižganje, zvonjenje ali drugi nenehni zvoki v ušesih
buzzing, hissing, whistling, ringing or other persistent noise in the ears
brenčanje, piskanje, žvižganje, zvonjenje ali drugi nenehni šumi v ušesih
BV CYCLOTRON VU - AMSTERDAM
BV CYCLOTRON VU
Bvb + IFNa
bevacizumabb + interferona
BW: Body weight, SD: Standard deviation
TM: telesna masa, SD: standardni odklon
By 1 year
V 1 letu
By 12 months
po 12 mesecih
By 2 years
V 2 letih
By 2 years 39%; P < .0001
po 2 letih 39%; P < 0,0001
By 24 hours there appears to be insignificant levels of vernakalant.
Kot kaže, je koncentracija vernakalanta po 24 urah zanemarljiva.
By 24 months
po 24 mesecih
By 3 years
V 3 letih
By 3 years 50%; P < .0001
po 3 letih 50%; P < 0,0001
by 31/03/2021
2021.
By 34 days after the initiation of treatment, 17.5 - 20.0% morbidity and 1.5 - 2.3% mortality were observed in the treated groups in comparison to 50.0 - 53.3% morbidity and 2.5 - 4.8% mortality in the untreated groups.
34 dni po začetku zdravljenja so v skupini, ki je bila zdravljena , zabeležili 17,5–20,0 % obolevnost in 1,5–2,3 % smrtnost v primerjavi s 50,0– 53,3 % obolevnostjo in 2,5–4,8 % smrtnostjo v skupini, ki ni bila zdravljena..
By 4 years
V 4 letih
By 4 years 40%; P < .0001
po 4 letih 40%; P < 0,0001
By 4 years By 5 years
po 4 letih po 5 letih
By 5 years
V 5 letih
By 5 years By 6 years 56%; P < .0001
po 5 letih po 6 letih 56%; P < 0,0001
by 50% and monitor
amlodipina za 50 % in
By 60 months, the incidence of non-skin malignancies was significantly higher in the cohort who continued ciclosporin as compared with the cohort who had ciclosporin withdrawn (8.4% vs.
Po 60 mesecih je bila incidenca ne-kožnih malignih bolezni signifikantno večja v kohorti, ki je nadaljevala s ciklosporinskim zdravljenjem, kot v kohorti, ki so ji ciklosporin ukinili (8,4 % proti
by a drip into a vein.
z infuzijo v veno.
By acting as a ligand trap, aflibercept prevents binding of endogenous ligands to their cognate receptors and thereby blocks receptor mediated signaling.
Ker aflibercept deluje kot ligand- past, prepreči vezavo endogenih ligandov na njihove sorodne receptorje in tako blokira signale, ki jih posredujejo receptorji.
By activating its receptors, Buccolam increases GABA’s effects, which will stop a convulsion.
Z aktiviranjem receptorjev zdravilo Buccolam poveča učinke živčnega prenašalca GABA, kar zaustavi epileptični napad.
By activating its receptors, imepitoin increases GABA’s effects and helps to prevent seizures.
Imepitoin z aktiviranjem receptorjev poveča učinke živčnega prenašalca GABA in pomaga preprečiti epileptične napade.
By activating its receptors, zaleplon increases GABA’s effects, which encourages sleep.
Zaleplon z aktiviranjem receptorjev poveča učinke GABA, kar spodbuja spanec.
by atazanavir
atazanavirjem
by atazanavir.
(2,06-5,16)
By attaching and blocking PCSK9, Praluent prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream.
Z vezavo na encim PCSK9 in njegovim zaviranjem zdravilo Praluent preprečuje razgradnjo receptorjev v celicah, kar poveča število teh receptorjev na celični površini, kjer se lahko vežejo na holesterol LDL ter ga odstranijo iz krvnega obtoka.
By attaching and blocking PCSK9, Repatha prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream.
Zdravilo Repatha z vezavo na encim PCSK9 in njegovim zaviranjem preprečuje razgradnjo receptorjev v celicah, kar poveča njihovo število na celični površini, kjer se lahko vežejo na holesterol LDL ter ga odstranijo iz krvnega obtoka.
By attaching itself to the protein, maraviroc prevents it from entering the cells.
Maravirok se veže na beljakovino in s tem prepreči vstop v celice.
By attaching to and blocking RANKL, denosumab reduces the formation and activity of the osteoclasts.
Z vezavo na antigen RANKL in njegovim zaviranjem denosumab zmanjšuje nastajanje in delovanje osteoklastov.
By attaching to CD20 on B- lymphocytes, obinutuzumab makes the B-lymphocytes a target for the body’s immune (defence) system, which kills the B-lymphocytes.
Obinuzuzumab z vezavo na CD20 na limfocitih B povzroči, da limfociti B postanejo tarča imunskega (obrambnega) sistema, ki jih ubije.
By attaching to CD20, ofatumumab stimulates the body’s immune system to attack the cancerous cells, helping to control the disease.
Ofatumumab z vezavo na CD20 spodbudi imunski sistem, da napade rakave celice, kar pripomore k obvladovanju bolezni.
By attaching to CD38 on the multiple myeloma cells, daratumumab activates the immune system to kill the cancer cells.
Z vezavo na beljakovino CD38 v celicah multiplega mieloma daratumumab aktivira imunski sistem, da uniči rakave celice.
By attaching to HER2, pertuzumab stops HER2 producing signals that cause the cancer cells to grow.
S tem prepreči, da bi beljakovina tvorila signale, ki spodbujajo rast rakavih celic.
By attaching to IgE, omalizumab ‘mops up’ the free IgE circulating in the blood.
Omalizumab si z vezavo na IgE „pripoji“ prosti IgE, ki kroži v krvi.
By attaching to IL-6, siltuximab blocks its activity and stops abnormal cell growth, thus reducing the size of the lymph nodes and the symptoms of the disease.
Ko se siltuksimab veže na interlevkin-6, prepreči njegovo delovanje in zaustavi nenormalno rast celic, zaradi česar se zmanjšajo velikost bezgavk in simptomi bolezni.
By attaching to integrin, natalizumab is thought to stop the leucocytes from going from the blood into the brain.
Natalizumab naj bi z vezavo na integrin levkocitom preprečeval prehod iz krvi v možgane.
By attaching to interleukin-1 beta, canakinumab blocks its activity, helping to reduce inflammation thereby relieving the symptoms of the diseases.
Kanakinumab z vezavo na interlevkin-1 beta zavre njegovo delovanje in tako pomaga zmanjšati vnetje, s tem pa ublažiti simptome bolezni.
By attaching to interleukin-5, mepolizumab blocks its action and thereby
S pritrditvijo na interlevkin-5 mepolizumab zavre njegovo delovanje in tako zmanjša število eozinofilcev.
By attaching to it, ramucirumab blocks this action, reducing the blood supply to the tumour and so slowing the growth of the cancer.
Ko se ramucirumab veže na ta receptor, zavira njegovo delovanje, s čimer zmanjša dotok krvi v tumor in s tem upočasni rast raka.
By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from the cancer cells from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells.
Z vezavo na receptor učinkovina nivolumab prepreči, da bi PD-1 in PD-2 v rakavih celicah izklopila celice T, s čimer poveča sposobnost imunskega sistema za uničevanje rakavih celic.
By attaching to the receptors that interleukin 1 would normally attach itself to, anakinra blocks the activity of interleukin 1, helping to relieve the symptoms of these diseases.
Anakinra z vezanjem na receptorje, na katere se običajno interlevkin 1 veže, prepreči delovanje interlevkina 1 in tako ublaži simptome teh bolezni.
By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.
Z vezavo na TNF adalimumab zavre njegovo delovanje in tako zmanjša vnetja in druge simptome bolezni.
By attaching to ‘VEGF receptor 2’ and blocking it the medicine cuts off the blood supply to the cancer cells.
S pritrditvijo na „receptor VEGF 2“ in z zaviranjem le-tega zdravilo prekine oskrbo rakavih celic s krvjo.
By background NRTI
Glede na osnovno shemo NRTI
By baseline CD4 count (x 106 cells/l)
Glede na začetno št. celic CD4 (106 celic/l)
By baseline CD4 count (x 106 cells/L)
Glede na začetno število CD4 (x 106 celic/l)
By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer lowers the phosphorus concentration in the serum.
Z vezavo fosfata v prebavnem traktu in zmanjšanjem absorpcije sevelamer znižuje koncentracijo fosfata v serumu.
By binding selectively to ATIII, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII.
S selektivno vezavo na ATIII fondaparinuks ojača (približno 300- krat) naravno nevtralizacijo Xa z ATIII.
By binding the shared p40 subunit of IL-12 and IL-23, ustekinumab may exert its clinical effects in psoriasis, psoriatic arthritis and Crohn’s disease through interruption of the Th1 and Th17 cytokine pathways, which are central to the pathology of these diseases.
Ustekinumab lahko z vezavo na podenoto p40 IL-12 in IL-23 in prekinitvijo poti citokinov Th1 in Th17, bistvenih pri patologiji psoriaze in psoriatičnega artritisa, spodbudi klinične učinke pri obeh boleznih.
By binding to the α4β7 integrin expressed on gut- homing lymphocytes, vedolizumab exerts an immunosuppressive effect on the gut.
Vedolizumab z vezavo na integrin α4β7, izražen na črevesnih limfocitih, zmanjšuje imunsko odzivnost v črevesu.
By binding to VEGF and PlGF, aflibercept stops them having an effect.
Ko se aflibercept veže na VEGF in PlGF, prepreči njuno delovanje.
By binding to α4β7 on certain lymphocytes, vedolizumab inhibits adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1).
Z vezavo na α4β7 na nekaterih limfocitih vedolizumab zavira adhezijo teh celic na mukozno adresinsko celično adhezijsko molekulo-1 (MAdCAM-1; “mucosal addressin cell adhesion molecule-1”), vendar ne za žilno celično adhezijsko molekulo-1 (VCAM-1; “vascular cell adhesion molecule-1”).
By blocking an enzyme called integrase, elvitegravir stops the virus’s genetic material from integrating into the genetic material of the cells it has infected.
Z zaviranjem encima, imenovanega integraza, elvitegravir prepreči vključitev genskega materiala virusa v genski material celic, ki jih je okužil.
By blocking Bcr-Abl kinase, as well as other kinases, Sprycel helps to control the spread of leukaemia cells.
Zdravilo Sprycel z zaviranjem BCR-ABL kinaze kot tudi drugih kinaz, pomaga nadzorovati širjenje levkemičnih celic.
By blocking Bcr-Abl kinase, Tasigna helps to control the spread of leukaemia cells.
Zdravilo Tasigna z zaviranjem Bcr-Abl kinaze pomaga nadzorovati širjenje levkemičnih celic.
By blocking Btk, ibrutinib decreases survival and migration of B lymphocytes, thereby delaying the progression of the cancer.
Ibrutinib z zaviranjem encima Btk zmanjša stopnjo preživetja in migracije limfocitov B, s čimer upočasni napredovanje raka.
By blocking factor Xa, it reduces the levels of thrombin in the blood, which reduces the risk of blood clots forming in the arteries and veins.
Z zaviranjem faktorja Xa se ravni trombina v krvi znižajo, kar zmanjša tveganje za nastanek krvnih strdkov v arterijah in venah.
By blocking factor Xa, the levels of thrombin decrease, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.
Z zaviranjem faktorja Xa se ravni trombina znižajo, kar zmanjša nevarnost za nastanek krvnih strdkov v venah in arterijah, zdravi pa tudi obstoječe strdke.
By blocking factor Xa, the medicine reduces the levels of thrombin in the blood, which helps treat clots and reduce the risk of them forming in the arteries and veins and leading to DVT, pulmonary embolism, stroke or other organ damage.
Z zaviranjem faktorja Xa zdravilo Lixiana zniža ravni trombina v krvi, s čimer pomaga odpraviti strdke in zmanjša tveganje, da bi se tvorili v arterijah in venah ter povzročili globoko vensko trombozo, pljučno embolijo, možgansko kap ali poškodbo drugih organov.